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Background: Respiratory syncytial virus (RSV) is a 
major contributor to lower respiratory tract infections 
worldwide and several vaccine candidates are cur-
rently in development. Following vaccine introduction, 
reliable RSV surveillance should enable monitoring of 
vaccination impact. Data on the RSV disease burden 
in the European Union and European Economic Area 
(EU/EEA) are sparse. Aim: The aim of this study was 
to gather knowledge on current practices of national 
RSV surveillance in the EU/EEA. Methods: National 
Coordinators and National Focal Points for Influenza 
(epidemiologists and virologists) from the EU/EEA 
countries (n = 31) were invited to participate in an 
online survey in August and September 2017. The 
questionnaire covered questions on epidemiological 
and laboratory aspects of RSV surveillance. Results: 
All EU/EEA countries except Liechtenstein replied to 
the survey. Eighteen countries reported to have a sen-
tinel surveillance system, 26 countries a non-sentinel 
surveillance system and three countries to have nei-
ther. RSV data collection was mostly done within the 
context of influenza surveillance. A wide range of 
diagnostic and characterisation assays was used for 
the detection of RSV. Discussion: The majority of EU/
EEA countries have some surveillance for RSV in place. 
The prevailing integration of RSV surveillance into the 
existing influenza sentinel surveillance system may 
lead to under-reporting of RSV. The documented vari-
ations in existing RSV surveillance systems and their 
outputs indicate that there is scope for developing 
guidelines on establishing comparable methods and 
outcomes for RSV surveillance across the EU/EEA, to 
ensure the availability of a consistent evidence base 
for assessing future vaccination programmes.
Introduction
Respiratory syncytial virus (RSV) is a major contribu-
tor to lower respiratory tract infections (LRTI) world-
wide [1]. It is estimated that RSV is responsible for 20 
to 50 million cases of acute LRTI each year in children 
younger than 5 years, resulting in a large number of 
hospitalisations. Infants are affected more than other 
age groups, representing an estimated 45% of all hos-
pital admissions and deaths from RSV [1]. The public 
health importance of RSV is due, at least in low-income 
settings, to its high morbidity and mortality in young 
children [2,3]. The disease burden among the elderly 
population is substantial as well, and may be similar 
to that of seasonal influenza A virus infection in some 
seasons [4-6].
Common symptoms of RSV infections in children 
usually include rhinorrhoea, cough, wheezing and 
low-grade fever. More severe presentations of RSV 
infections such as bronchiolitis, pneumonia and atypi-
cal extrapulmonary disease [7] can lead to hospi-
talisation. Comorbidities such as chronic lung and/or 
heart disease increase the risk of severe RSV disease. 
Importantly, natural immunity to RSV is not long-last-
ing which means that individuals are at risk of reinfec-
tions throughout their lifetime [8].
RSV is an enveloped virus, with a linear negative-sense 
single-stranded RNA genome, and belongs to the spe-
cies  Human orthopneumovirus. It contains 10 genes 
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encoding 11 proteins, among which are the nucleopro-
tein (N), the glycoprotein (G) and the fusion protein 
(F). Laboratory detection of RSV infections uses anti-
gen detection, nucleic acid amplification based assays 
and/or virus culture. RSV is divided into types A and 
B based on antigenic properties of the glycoprotein 
G. Both subtypes usually co-circulate during epidemic 
seasons, following an irregular, alternating prevalence 
pattern, subtype A having a higher cumulative preva-
lence than subtype B [9-12]. Most commonly, the G 
gene region is used for molecular typing. However, 
as the RSV genome is more variable than previously 
thought, genotyping by sequencing of selected genes 
or the whole genome is being investigated [13-15]. 
Repeated RSV infections are common and have been 
documented for both children and adults, while infec-
tions tend to be less severe after the first infection 
episode [16,17]. The host’s immune status and the anti-
genic properties of current circulating RSV strains com-
pared with previous infecting strains are thought to be 
factors influencing the risk of reinfections [18].
To prevent RSV infection in high-risk groups such as 
infants with chronic lung or congenital heart disease 
and infants born preterm, it is recommended to admin-
ister a neutralising monoclonal antibody (Palivizumab) 
monthly in these groups as prophylaxis during the RSV 
season [19]. Monoclonal antibodies with extended 
half-life are in development [20]. Several RSV vaccine 
candidates are currently undergoing development and 
testing including live-attenuated vaccines and different 
types of constructs, e.g. particle-based and subunit 
vaccines as well as recombinant vectors. The first can-
didate in clinical trials to complete phase III evaluation 
was a pre-fusion F protein nanoparticle-based vaccine. 
The trial aimed to reduce the rate of medically signifi-
cant RSV LRTI in infants in the first 90 days of life, but 
failed its primary endpoint (39% efficacy against medi-
cally significant RSV LRTI (97.5% confidence interval 
(CI): −1 to 64)), although an efficacy of 44% (95% CI: 
20–62) against RSV LRTI hospitalisations was found 
[21]. Target populations for the different vaccines differ 
and include young children, older adults and pregnant 
women, and despite the failure of the above-mentioned 
vaccine, it is still expected that an RSV vaccine will be 
available in Europe in coming years [22,23].
To assess the impact of a future RSV vaccine, valid esti-
mates of disease morbidity and mortality are essential. 
Also, generating data on RSV burden and identifying 
risk groups in the population is fundamental to raise 
awareness among the population, inform healthcare 
professionals and policymakers and support vaccine 
deployment. After introduction of RSV vaccination, 
a stable surveillance system will permit monitoring 
the effect of vaccination including vaccine effective-
ness and impact on disease burden. Although data on 
RSV detections are available from several European 
countries [24], data on RSV disease burden within the 
European Union (EU) are at present still sparse [22]. 
There is currently no harmonised case definition or 
reporting system, which would be a prerequisite for 
comparison of surveillance data across regions and 
over time. In addition, uniform guidelines for RSV 
strain characterisation, including detailed sequence 
analysis and antigenic characterisation, are critical for 
the detection of changes in circulating strains following 
implementation of vaccination.
The objective of the present survey, conducted among 
all EU and European Economic Area (EEA) countries 
during August and September 2017, was to gather 
knowledge on the current practices of RSV epidemio-
logical and laboratory surveillance. This knowledge 
could identify best practice and provide benchmarking 
data and thereby inform and strengthen RSV surveil-
lance in the EU/EAA countries, particularly in view of 
the likely need for monitoring RSV vaccine effective-
ness and impact in the future.
Methods
The European Centre for Disease Prevention and Control 
(ECDC) National Coordinators, and National Focal and 
Operational Contact Points for Influenza from EU/EEA 
countries were invited to participate in the survey. 
The online questionnaire on the EUSurvey platform 
(https://ec.europa.eu/eusurvey/) covered questions 
on both epidemiological and laboratory aspects of RSV 
infection surveillance (Supplement 1). Epidemiologists 
and virologists from the national public health organi-
zations responded to the epidemiology and laboratory-
related sections of the survey, respectively.
Online questionnaire
The questionnaire was divided into five sections. The 
first section covered general questions about RSV sur-
veillance in the country. The second and third sections 
covered questions related to sentinel and non-sentinel 
epidemiological RSV surveillance, respectively. Within 
each section, specific subsections allowed respond-
ents to report detailed information on different sys-
tems (for example community surveillance by general 
practitioners (GPs) or hospital surveillance by paedi-
atric intensive care units). The fourth section of the 
questionnaire related to laboratory identification of 
RSV and further characterisation of the virus into types 
A and B and genotypes, as well as laboratory capac-
ity. Respondents were provided with a definition of the 
terms typing and genotyping used in the questionnaire: 
typing referred to the distinction of RSV types A and B 
and genotyping to characterisation of genotypes within 
A and B types. Respondents were asked about meth-
ods used for RSV detection and characterisation in 
diagnostic and surveillance laboratories. Respondents 
had the possibility to provide more than one answer, 
but an estimate of the number of laboratories perform-
ing each method was not requested. The fifth section 
addressed aspects of reporting and sharing RSV data. 
Each question comprised a comment box for further 
explanations. To allow more flexibility in filling the 
questionnaire, no question was mandatory and the 
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epidemiological and laboratory parts of the question-
naire could be filled independently.
Study period
The invitation to participate in the survey was sent out 
on 9 August 2017, with a final deadline for responding 
on 15 September 2017. Data from the online question-
naire was exported to, and analysed in Excel. Data 
analysis was performed in two phases. Following 
the initial data cleaning process, respondents were 
contacted again (October–November 2017) to clarify 
answers when necessary.
Ethical statement
Ethical approval was not needed for this survey.
Results
Response rate
All EU/EEA countries, except Liechtenstein (n = 30/31) 
responded to the questionnaire. In some countries, two 
institutions provided responses, for example Greece 
(National Influenza Centre (NIC)–Southern Greece 
and NIC–Northern Greece), the United Kingdom (UK) 
(England and Northern Ireland) and Spain (Valladolid 
National Influenza Center In Castile and Leon and 
Instituto de Salud Carlos III).
Sentinel surveillance
Sentinel surveillance systems are systems that have 
been set up for surveillance as primary goal. While they 
usually cover only a small part of the population, they 
are high-quality networks that systematically sample 
patients that fulfil the criteria in the case definition and 
are representative of the population. Of 30 countries, 
18 reported to have a sentinel surveillance system that 
includes RSV: Austria, Belgium, Bulgaria, the Czech 
Republic, Denmark, Estonia, Finland, France, Germany, 
Hungary, Ireland, Latvia, the Netherlands, Poland, 
Portugal, Slovakia, Slovenia and the UK. Four of these 
countries reported the existence of multiple sentinel 
systems (Austria (n = 2), Belgium (n = 3), France (n = 2) 
and Slovakia (n = 2)). In total, 23 surveillance systems 
identified in 18 countries included RSV. Details on each 
system are provided in Supplement 2.
All sentinel surveillance systems, except for the RSV 
laboratory sentinel surveillance in Belgium and the 
hospital and GP surveillance in France, were part of 
influenza surveillance systems which were in most 
countries designed to capture patients with influ-
enza-like-illness (ILI). All countries with sentinel sur-
veillance systems had at least one system operated 
through GPs. Eleven countries reported GP practices 
as the operating health facility, seven other countries 
reported a combination of GPs with other practition-
ers such as school or family doctors, paediatricians or 
emergency unit. Four countries reported multiple sen-
tinel systems. In addition to GP surveillance, Austria, 
France and Slovakia also had a system that was hospi-
tal-based and Belgium additionally reported hospital-
based and laboratory-based systems.
Nine of 23 sentinel surveillance systems were active 
throughout the whole year and 12 systems during 
the influenza surveillance period (weeks 40–20). 
The reporting frequency was weekly for 21 systems. 
Reporters from 12 systems provided case-based data 
Table 1
Objectives and relevance of national respiratory syncytial virus surveillance, EU/EEA countries, September 2017
Chosen responses in the questionnaire Number of responding countries
Objectives of national RSV surveillance (n = 22)
Contribute to the overall understanding of the role of RSV in respiratory disease 16
Determine the seasonality of RSV, monitor trends of RSV detections within and across RSV seasons and the 
impact of potential vaccination programs per age/target group 14
Support the estimation of healthcare burden of RSV infection in the different age and target groups 9
Measure the impact of potential future RSV vaccination programmes (by collecting baseline data) 8
Track the prevalence of the two RSV types among circulating strains 5








Do not know 3
EU/EEA: European Union/European Economic Area; RSV: respiratory syncytial virus.
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Table 2a
Laboratory capacity for respiratory syncytial virus detection, typing and genotyping, EU/EEA, September 2017
Chosen responses in the questionnaire Number of responding countries
Diagnostics of RSV at primary laboratory (n = 27)
Real-time RT-PCR methods 22
Gel-based RT-PCR methods 2
Antigen detection (DFA, EIA, etc.) 13
Point of care test 9
Virus isolation 3
Other, including serology 3
Unknown 4
Primary diagnostics of RSV at the national laboratory (n = 28)
Real-time RT-PCR methods 27
Gel-based RT-PCR methods 5
Antigen detection (DFA, EIA, etc.) 8
Rapid test 1
Virus isolation 9
Other, including serology 7
Unknown 0










Other (NxTAG RPP Luminex assay) 1
Unknown 5
Methods used for typing RSV (n = 15)
One real-time RT-PCR for RSV A and B (with two probes for detection) 6
RSV A- and B-specific singleplex real-time RT-PCR 3
One RT-PCR for RSV A and B followed by sequencing 1
RSV A- and B-specific singleplex RT-PCR followed by sequencing 1
Other 5












DFA: direct immunofluorescence assay; EIA: enzyme immunoassay; EQA: external quality assessment; EU/EEA: European Union/European 
Economic Area; NxTAG RPP: NxTAG respiratory pathogen panel; QCMD: quality control for molecular diagnostics; RSV: respiratory syncytial 
virus.
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to the national level, nine provided aggregated data. 
For two systems, no information was filled out on the 
aggregation level of collected data. Five systems rep-
resented less than 1% of the population, four systems 
between 1% and 5% of the population, and four systems 
more than 5% of the population. Eligibility for sampling 
was specified for 16 systems: 10 used ILI cases, three 
combined ILI and acute respiratory infection (ARI), two 
used ARI only and two used severe acute respiratory 
infection (SARI).
Non-sentinel surveillance
As opposed to sentinel surveillance, non-sentinel 
surveillance is mostly a passive surveillance system 
that collects notifications of reported cases or labo-
ratory results. A denominator for the source popula-
tion is not always provided. There were 26 countries 
with a non-sentinel surveillance system for RSV; 
Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech 
Republic, Denmark, Estonia, Finland, France, Germany, 
Greece, Hungary, Iceland, Ireland, Latvia, Malta, the 
Netherlands, Norway, Poland, Portugal, Romania, 
Spain, Slovenia, Sweden and the UK. Six of them 
reported two non-sentinel systems: Finland, Iceland, 
Ireland, the Netherlands, Poland and Sweden. In total, 
there were 32 non-sentinel surveillance systems in 26 
countries; details on the individual systems are pro-
vided in Supplement 2). Of 32 non-sentinel surveillance 
systems, 16 were laboratory-based, 13 were hospital-
based, one was both hospital-based and GP-based, 
and two were other systems.
Many countries reported that their non-sentinel surveil-
lance system was part of influenza surveillance (13/32 
reported systems), three were specifically for RSV, 14 
were part of another surveillance system and two were 
RSV-related studies. Twenty-two surveillance systems 
that reported on the surveillance period were active 
Chosen responses in the questionnaire Number of responding countries





Methods used for genotyping RSV (n = 9)
RT-PCR and Sanger sequencing 9
Next generation sequencing 0
Other 0
Total number of RSV samples genotyped annually (n = 7)
< 100 6
100–500 1






Planning to introduce new methods for RSV typing and/or genotyping in the future (n = 28)
Next generation sequencing method 12
Sanger sequencing method 8
Real-time PCR assay 5
No 8
Unknown 3
Participation in quality assessment programmes for RSV detection or characterisation (n = 29)
EQA (e.g. QCMD) for RSV detection and/or typing every year 19
EQA for RSV characterisation every year 2
Other (e.g. do not participate every year, etc.) 3
No 8
Unknown 0
DFA: direct immunofluorescence assay; EIA: enzyme immunoassay; EQA: external quality assessment; EU/EEA: European Union/European 
Economic Area; NxTAG RPP: NxTAG respiratory pathogen panel; QCMD: quality control for molecular diagnostics; RSV: respiratory syncytial 
virus.
Table 2b
Laboratory capacity for respiratory syncytial virus detection, typing and genotyping, EU/EEA, September 2017
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throughout the whole year and eight during the influ-
enza surveillance period (weeks 40–20). Of 23 systems 
for which data on reporting frequency was available, 
one reported monthly and 22 reported on a weekly 
basis. About half of the reported data were case-based 
(13/28 systems that reported on the aggregation level) 
compared with 15/28 systems that collected aggre-
gated data. The percentage of the population covered 
by the non-sentinel system was reported as known in 
five of the systems. The number of tested specimens 
was known in 10 systems.
Countries without respiratory syncytial virus 
surveillance
Three countries (Italy, Lithuania and Luxembourg) 
reported not having a surveillance system that includes 
RSV at the time of the survey (summer 2017). Of these 
countries, Italy and Luxembourg were interested in set-
ting up a surveillance system that includes RSV in the 
next 3 years. Their preferred system would be GP- and 
laboratory-based surveillance. Luxembourg indeed 
introduced RSV surveillance for the northern hemi-
sphere winter season 2018/19 by conducting RSV test-
ing on samples collected from the influenza sentinel 
surveillance.
Objectives of respiratory syncytial virus 
surveillance
The two most common objectives of RSV surveillance 
among the 22 countries responding to the questions 
about the objectives (Table 1) were to contribute to the 
overall understanding of the role of RSV in respiratory 
disease (n = 16/22) and to determine seasonality of RSV, 
monitor trends of RSV detections within and across 
RSV seasons and the impact of potential vaccination 
programmes per age and/or target group (n = 14/22). 
Additional objectives not presented in Table 1 were to 
collect information in order to prescribe prophylaxis 
(n = 1) and to measure overall incidence and trends 
(n = 1). Four countries did not report objectives of their 
surveillance system.
The opinion of respondents of most countries was that 
RSV surveillance is relevant nationally (25 of 30 coun-
tries) as well as internationally (24 of 30 countries), 
see Table 1.
Communication
Twenty-one countries provided information about com-
municating RSV surveillance data. Information about 
RSV surveillance is mostly shared with clinicians 
(19/21), public health professionals (18/21) and labora-
tories (17/21) but also with the public (15/21), the scien-
tific community (10/21) and policymakers (10/21). One 
country did not communicate findings. Results were 
mostly communicated through national surveillance 
bulletins, websites and reports (19/20), scientific arti-
cles (11/20), media (6/20) and social media (4/20).
Laboratory capacity
All 30 countries provided information on laboratory 
capacity at primary and national laboratory levels, and 
information by Member State reflects both sources 
(Table 2).
Capacity at diagnostic laboratories
The respondents were asked about capacity for RSV 
detection in diagnostic laboratories across the country, 
based on their knowledge. Information on the number 
of laboratories performing such testing was provided by 
22 countries (Table 2). In these countries, the number 
of laboratories performing RSV detection varied greatly 
from one to ca 60. Importantly, among all countries for 
which information was provided, all but one reported 
capacity for PCR-based detection of RSV at diagnostic 
laboratory level. In the country where PCR detection 
was not performed at diagnostic laboratories, the pri-
mary test used was antigen detection. Eleven countries 
reported availability of typing capacity for RSV A and B 
in some diagnostic laboratories.
Respiratory syncytial virus laboratory surveillance
Fifteen countries (Austria, Belgium, Bulgaria, the 
Czech Republic, Denmark, Finland, France, Germany, 
Ireland, Latvia, Portugal, Romania, Spain, Sweden and 
the UK) reported having a laboratory designated for 
RSV reference functions, while 13 reported not having 
such a laboratory. Eleven countries indicated that the 
reference laboratory received samples from sentinel 
and/or non-sentinel surveillance systems.
Technical capacity for respiratory syncytial virus 
detection, typing and genotyping at the central level
Twenty-seven of 28 countries performed a real-time 
RT-PCR based assay for RSV detection at the labora-
tory that responded to the survey (Table 2). In Hungary, 
assays based on antigen detection and virus isolation 
were used at the central laboratory to detect RSV (no 
information was provided regarding methods used at 
hospital diagnostic laboratories).
Seven countries reported not performing RSV typing. In 
the countries that performed RSV typing and provided 
information on the targeted gene (n = 15), the N gene 
was most often targeted (n = 13), with real-time RT-PCR 
being the predominant method. Among five countries 
using a method not listed in the questionnaire, four 
used a multiplex real-time RT-PCR that detected RSV-A 
and RSV-B together with other viruses, and one coun-
try, Ireland, used a PCR-based NxTAG Luminex multi-
plex assay.
Ten countries reported performing RSV genotyping. 
Nine countries provided information on the assays 
used for genotyping, which always included (but were 
not necessarily limited to) the G gene and a protocol 
involving Sanger sequencing (Table 2).
Sixteen of 22 laboratories in 19 countries received and/
or identified fewer than 500 RSV-positive samples a 
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year. Six countries provided information showing that 
all RSV-positive samples received at the central labo-
ratory were typed (France, Latvia, the Netherlands, 
Portugal, Romania and Slovenia). Seven countries per-
formed genotyping on a subset of detected RSV speci-
mens (fewer than 100 annually for six of them). The 
reported success rate for typing was high, more than 
80% in 13 of 16 responses. Four respondents only pro-
vided an estimate of their success rate for genotyping 
which indicated that when they performed genotyp-
ing, they had a high success rate. Nineteen countries 
intended to introduce typing and/or genotyping and to 
upgrade methods towards sequencing and next gen-
eration sequencing. Finally, two thirds of the respond-
ents (17/29) indicated that their laboratory participated 
in external quality assessment (EQA) for the identifica-
tion of RSV.
Discussion
Of 30 responding EU/EEA countries, 27 reported having 
a surveillance system for RSV in place. Half of the coun-
tries had a sentinel surveillance system for RSV and 26 
countries a non-sentinel surveillance system. These 
systems varied from very basic (e.g. aggregated data, 
limited clinical information) to more advanced (e.g. 
case-based, extensive clinical information). In all but 
one of the responding countries, RSV sentinel surveil-
lance was part of influenza surveillance. Previous stud-
ies have shown that a RSV surveillance system could 
be built upon an existing influenza surveillance system 
[25,26]. Most sentinel surveillance systems in our sur-
vey were based on samples collected by GP practices 
while most non-sentinel systems were laboratory- or 
hospital-based.
The most common objective of the reported surveil-
lance systems was to contribute to overall understand-
ing of the role of RSV in respiratory disease. However, 
less than half of the countries reported disease burden 
or estimation of the impact of RSV vaccination pro-
grammes as an objective of their surveillance system. 
Understanding seasonality helps countries to make 
recommendations regarding the timing of the provi-
sion of monoclonal antibodies which are available for 
treatment and prophylaxis in the first year(s) of life, 
mainly for premature children [25,26]. If assessment 
of seasonality is the only or primary surveillance goal 
of a country, a non-sentinel surveillance system based 
on laboratory results or a subset of RSV cases may be 
sufficient. RSV-specific incidence data on less severe 
cases, i.e. patients that report to the GP or other pri-
mary care health facilities seems well-established in 
60% of the European countries through primary care 
sentinel surveillance. Hospital surveillance will, how-
ever, be crucial to estimate the incidence of severe 
cases and to assess efficacy and effectiveness of RSV 
vaccines and monoclonal antibodies to prevent compli-
cations following infection. At the time of our survey, 
only four countries had an RSV sentinel hospital sur-
veillance in place and would be able to provide such 
data, although a third of the countries indicated that 
measuring the impact of potential future vaccination 
programmes was a surveillance goal. Strengthening 
surveillance to detect more severe cases of RSV, e.g. 
as part of a SARI surveillance, should therefore be a 
main priority for countries aiming to assess vaccina-
tion impact. In order to produce reliable incidence 
data, denominator data will be essential in any of these 
systems.
A wide range of methods were used by diagnostic labo-
ratories for the detection of RSV, with assays based on 
RT-PCR and antigen detection most frequently reported. 
However, no further information was collected on the 
use of RSV-specific vs multiplex respiratory virus diag-
nostic assays. As the use of RT-PCR over antigen detec-
tion for RSV in clinical settings has been increasing, 
the performance of surveillance systems has improved 
[27,28]. The variety of assays used may challenge com-
parison and generalisability of data across the EU/EAA 
and highlights the need for diagnostic laboratories to 
participate in an EQA for RSV detection.
While RSV surveillance was in place in 27 of the 30 
surveyed countries, representing a clear increase 
from countries reporting to the European Influenza 
Surveillance System in 2007 [26], this study highlights 
the heterogeneity of these systems. For example, some 
countries had both a sentinel and non-sentinel sys-
tem, had clear definitions for who should be sampled 
and/or collected additional clinical information, while 
others did not. National surveillance, based either on 
GP (community) visits or (paediatric) hospital and/or 
intensive care admissions, is crucial to monitor epi-
demic trends, define disease burden (e.g. to inform 
cost-effectiveness studies for available vaccines) and 
guide national decision making. Harmonisation of sur-
veillance across the EU/EEA countries would have the 
additional value of enabling supranational analyses to 
improve the power of statistical analyses and to pro-
vide insights in geographic and demographic varia-
tions that cannot be observed on a national level [24]. 
Also, it should be discussed among the EU/EEA coun-
tries how RSV-surveillance should be ideally designed 
and how every country could contribute; it may not be 
necessary for every country to have the same system, 
but rather systems that complement each other on the 
European level.
In most countries, RSV surveillance was based on influ-
enza sentinel surveillance systems and on samples 
from ILI or ARI cases. This has clear practical and finan-
cial advantages because the same sample can be used 
for both tests or logistics can be shared when different 
samples are used, and results of laboratory outcomes 
can be compared. However, it is important that adding 
an RSV component to influenza surveillance does not 
impair the current well-established influenza surveil-
lance systems [29]. Currently, the WHO is performing 
a pilot study which aims to test whether it is feasible 
to make use of the Global Influenza Surveillance and 
Response System platform for RSV surveillance without 
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adversely affecting the well-established ILI and SARI 
surveillance of influenza [30]. The first results of this 
pilot are encouraging and even indicated that combin-
ing RSV and influenza surveillance can be an advan-
tage to the current influenza surveillance systems [31].
Often, both ILI case definitions at GP level and SARI 
definitions at hospital level include fever. These defini-
tions are not sensitive enough for RSV cases, which can 
typically present with and without fever, and the sam-
pling algorithms used in influenza sentinel sites may 
need to be adjusted. Therefore, the WHO RSV initiative 
has extended the ILI case definition to include also 
cases without fever [30]. A recent review of RSV cases 
reported through sentinel and non-sentinel sites in the 
EU/EEA showed clearly that most, if not all RSV cases 
are captured in the influenza surveillance period from 
week 40 to week 20 in the following year, while several 
influenza systems have year-round data [24]. However, 
that study also showed that RSV often starts circulat-
ing in or close to week 40, suggesting that very early 
onset of the RSV season can occur and would not be 
captured if surveillance is limited to the typical influ-
enza surveillance period. In addition, not all sentinel 
systems may capture paediatric populations, if there is 
no specific focus on infants. Some countries systemati-
cally test samples from sentinel systems also for other 
respiratory viruses, notably by using published and/or 
adapted multiplex PCR assays [32,33]. These surveil-
lance systems can be used efficiently to detect circu-
lating respiratory viruses such as rhinovirus and also 
to rapidly set up surveillance for novel or re-emerging 
viruses such as enterovirus D68 [34,35].
The capacity to detect RSV using molecular methods 
was available in almost all EU/EEA countries. However, 
different assays were used and different genes tar-
geted. Real-time PCR was reported to be the most 
commonly used assay and two thirds of the laborato-
ries reported annual participation in an EQA, demon-
strating their commitment to assuring quality of the 
results. Both for RSV A and RSV B, detection perfor-
mance can vary considerably depending of the type of 
assay used; in particular real-time RT-PCR and nested 
RT-PCR performed better than conventional RT-PCR and 
commercial assays [36]. In a recent systematic review 
and meta-analysis, the sensitivity of rapid RSV anti-
gen diagnostic tests was estimated at 74% and 88% 
when test results were compared with that of RT-PCR 
and immunofluorescence, respectively [37]. The survey 
conducted here was aimed mainly at providing infor-
mation on laboratory capacity at central level where 
testing for active surveillance systems are performed; 
it did not permit to review in detail what capacity exists 
in passive surveillance systems using data from diag-
nostic laboratories in each country (e.g. percentage of 
diagnostic laboratories performing RSV detection or 
EQA).
Data on strains circulating before and after vaccine 
introduction will provide important information on 
the impact of vaccination as some vaccine candidates 
may impact the circulation of certain virus subtypes 
as is known for e.g. influenza vaccines and rotavirus 
vaccines. While genotyping can be at least partially 
achieved using Sanger sequencing, many countries 
reported to be willing and able to move towards next 
generation sequencing. Irrespective of the sequenc-
ing method, the time interval before deployment of 
effective vaccines provides an excellent opportunity 
to increase the general capacity for genotyping of 
RSV, including generation of new important knowledge 
about vaccine preventability at virus strain level. These 
efforts will also contribute to increasing general capac-
ity for molecular epidemiology and surveillance at the 
European level.
Conclusions
This survey demonstrates that almost all EU/EEA 
Member States have surveillance activities related 
to RSV. However, objectives of the surveillance vary 
between countries. In order to prepare for the possible 
introduction of RSV vaccines onto European markets, 
RSV surveillance should be strengthened and surveil-
lance objectives need to be well-established. If the 
current primary aim is to determine seasonality, trends 
and to increase understanding of RSV, as pointed out 
as goals by the majority of responders, the surveil-
lance systems should include both epidemiological 
and laboratory components and be applied as system-
atically as possible throughout the year. However, for 
the burden and risk group estimations needed before 
and after introducing vaccination programmes, more 
comprehensive studies would be required that are not 
necessarily continuous. The current pre-vaccination era 
should be used to obtain valid baselines for RSV bur-
den and molecular epidemiological profiles, including 
the variability of antigenic sites targeted by vaccina-
tion, in order to effectively monitor post-immunisation 
changes. Once a vaccine is introduced, surveillance 
has an essential role to play in monitoring its impact 
and potential vaccine-induced changes in the circulat-
ing viruses and in informing policymakers.
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